Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 7,193 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 311,143 shares of the company’s stock after purchasing an additional 7,193 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Teva Pharmaceutical Industries were worth $6,858,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TEVA. Creative Planning grew its holdings in shares of Teva Pharmaceutical Industries by 4.5% in the third quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after acquiring an additional 1,863 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after acquiring an additional 1,094 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Private Advisor Group LLC now owns 26,104 shares of the company’s stock valued at $470,000 after acquiring an additional 2,990 shares in the last quarter. GHP Investment Advisors Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,681.4% in the third quarter. GHP Investment Advisors Inc. now owns 32,065 shares of the company’s stock valued at $578,000 after acquiring an additional 30,265 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its holdings in shares of Teva Pharmaceutical Industries by 95.3% in the third quarter. Diversify Advisory Services LLC now owns 19,859 shares of the company’s stock valued at $365,000 after acquiring an additional 9,693 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 0.0 %

NYSE:TEVA opened at $16.75 on Tuesday. The company has a market cap of $18.97 billion, a P/E ratio of -11.55, a P/E/G ratio of 1.44 and a beta of 0.71. The stock’s fifty day moving average price is $19.93 and its two-hundred day moving average price is $18.50. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.55% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent analyst reports. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.